Dementia with Lewy Bodies (DLB) is the second most common neurodegenerative dementia, accounting for 10-15% of all dementia cases[1]. Accurate diagnosis is challenging due to overlapping features with Alzheimer's disease (AD) and Parkinson's disease dementia (PDD). This page provides comprehensive coverage of diagnostic methods for DLB, including clinical assessments, biomarker testing, and specialized investigations.
DLB diagnostic criteria were last updated in 2017 by the Consortium on DLB[2]. The diagnosis relies on a combination of core clinical features, suggestive features, and biomarker evidence.
REM Sleep Behavior Disorder is one of the most sensitive early biomarkers for DLB, often predating the onset of cognitive and motor symptoms by 10-15 years[3]. RBD results from the loss of muscle atonia during REM sleep, allowing patients to physically act out their dreams.
Polysomnography (PSG) is required for definitive RBD diagnosis[4]:
Electromyography (EMG) Findings:
Recommended thresholds for REM sleep without atonia:
18% of REM sleep epochs with sustained chin EMG elevation (tonic)
15 minutes of REM sleep with phasic EMG activity in the submentalis muscle
Olfactory dysfunction is nearly universal in DLB and often appears in the prodromal stage[5]. The University of Pennsylvania Smell Identification Test (UPSIT) is the gold standard for assessing olfactory function.
| UPSIT Score | Interpretation |
|---|---|
| 0-19 | Severe dysfunction — highly suggestive of DLB |
| 20-25 | Moderate dysfunction — supports DLB diagnosis |
| 26-33 | Mild dysfunction — equivocal |
| ≥34 | Normal — argued against DLB |
Differential diagnostic value:
Cardiac I-123 metaiodobenzylguanidine (MIBG) scintigraphy assesses cardiac sympathetic innervation[6]. DLB and PD show marked reduction in cardiac MIBG uptake due to peripheral sympathetic denervation.
| Parameter | Threshold | Interpretation |
|---|---|---|
| Early H/M ratio | <2.0 | Abnormal |
| Delayed H/M ratio | <1.6 | Abnormal |
| Washout rate | >40% | Abnormal |
Combined criteria for DLB:
Contraindications:
CSF analysis supports DLB diagnosis and helps differentiate from AD[7]:
| Biomarker | DLB Pattern | AD Pattern | Interpretation |
|---|---|---|---|
| Total tau (t-tau) | Moderately elevated | Elevated | t-tau lower in DLB vs. AD |
| Phosphorylated tau (p-tau) | Normal or mildly elevated | Elevated | p-tau lower in DLB vs. AD |
| t-tau/p-tau ratio | Lower (~8-12) | Higher (~15-20) | Ratio <12 favors DLB |
| Alpha-synuclein | May show seeding | Normal | RT-QuIC showing pathology |
Alpha-synuclein seeding assays:
Emerging blood biomarkers show promise for DLB diagnosis[8]:
| Biomarker | DLB Change | Utility |
|---|---|---|
| Neurofilament light chain (NfL) | Elevated | Correlates with disease severity |
| Phosphorylated neurofilament heavy chain (pNfH) | Elevated | Potential differential marker |
| Alpha-synuclein RT-QuIC | Detectable | Seed amplification assays |
| GFAP | May be elevated | Astrocyte activation marker |
| UCH-L1 | Variable | Neuronal damage marker |
Note: Blood-based biomarkers require further validation before routine clinical use.
Epidemiology of Dementia with Lewy Bodies. Lancet Neurology. 2022. ↩︎
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017. ↩︎
REM sleep behavior disorder and prodromal neurodegeneration. Nature Reviews Neurology. 2023. ↩︎
International Classification of Sleep Disorders, 3rd Edition (ICSD-3). American Academy of Sleep Medicine. 2014. ↩︎
Olfactory dysfunction in neurodegenerative diseases. Brain. 2023. ↩︎
Cardiac MIBG scintigraphy in DLB diagnosis. Neurology. 2021. ↩︎
Cerebrospinal fluid biomarkers in DLB. Alzheimer's & Dementia. 2023. ↩︎
Blood biomarkers for neurodegenerative dementias. Nature Reviews Neurology. 2023. ↩︎